Basilea Pharmaceutica AG (LON:0QNA)
48.65
+0.05 (0.10%)
At close: Oct 21, 2025
Basilea Pharmaceutica AG Revenue
Basilea Pharmaceutica AG had revenue of 103.96M CHF in the half year ending June 30, 2025, with 22.44% growth. This brings the company's revenue in the last twelve months to 236.21M, up 58.51% year-over-year. In the year 2024, Basilea Pharmaceutica AG had annual revenue of 208.54M with 32.30% growth.
Revenue (ttm)
236.21M CHF
Revenue Growth
+58.51%
P/S Ratio
2.59
Revenue / Employee
1.44M CHF
Employees
164
Market Cap
561.13M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
Dec 31, 2020 | 127.63M | -6.75M | -5.02% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
Hikma Pharmaceuticals | 2.35B |
ConvaTec Group | 1.72B |
Spire Healthcare Group | 1.55B |
Genus | 672.80M |
Basilea Pharmaceutica AG News
- 4 weeks ago - Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - GlobeNewsWire
- 5 weeks ago - Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062 - GlobeNewsWire
- 2 months ago - Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - Basilea Pharmaceutica AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Basilea Pharmaceutica AG GAAP EPS of CHF 1.26, revenue of CHF 104M; updates FY outlook - Seeking Alpha
- 2 months ago - Basilea on track with strong 2025 half-year results - GlobeNewsWire
- 2 months ago - Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic - GlobeNewsWire
- 5 months ago - Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica) - GlobeNewsWire